Gene transfer to both cone and rod photoreceptors (PRs) is essential for gene therapy of inherited retinal degenerations that are caused by mutations in genes expressed in both PR types. Vectors based on the adeno-associated virus (AAV) efficiently transduce PRs of different species. However, these are predominantly rods and little is known about the ability of the AAV to transduce cones in combination with rods. Here we show that AAV2/8 transduces pig cones to levels that are similar to AAV2/9, and the outer nuclear layer (mainly rods) to levels that are on average higher, although not statistically significant, than both AAV2/5 and AAV2/9. We additionally found that the ubiquitous cytomegalovirus (CMV), but not the PR-specific GRK1 promoter, transduced pig cones efficiently, presumably because GRK1 is not expressed in pig cones as observed in mice and humans. Indeed, the GRK1 and CMV promoters transduce a similar percentage of murine cones with the CMV reaching the highest expression levels. Consistent with this, the AAV2/8 vectors with either the CMV or the GRK1 promoter restore cone function in a mouse model of Leber congenital amaurosis type 1 (LCA1), supporting the use of AAV2/8 for gene therapy of LCA1 as well as of other retinal diseases requiring gene transfer to both PR types.
Get full access to this article
View all access options for this article.
References
1.
AhneltP.K. (1998). The photoreceptor mosaic. Eye, 12, 531–540.
2.
AlloccaM., MussolinoC., Garcia-HoyosM., et al. (2007). Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J. Virol., 81, 11372–11380.
3.
AshtariM., CyckowskiL.L., MonroeJ.F., et al. (2011). The human visual cortex responds to gene therapy-mediated recovery of retinal function. J. Clin. Invest., 121, 2160–2168.
4.
BaehrW., KaranS., MaedaT., et al. (2007). The function of guanylate cyclase 1 and guanylate cyclase 2 in rod and cone photoreceptors. J. Biol. Chem., 282, 8837–8847.
5.
BainbridgeJ.W., SmithA.J., BarkerS.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358, 2231–2239.
6.
BeltranW.A., CideciyanA.V., LewinA.S., et al. (2012). Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc. Natl. Acad. Sci. USA, 109, 2132–2137.
7.
BennettJ., MaguireA.M., CideciyanA.V., et al. (1999). Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc. Natl. Acad. Sci. USA, 96, 9920–9925.
8.
BirchD.G., HoodD.C., NusinowitzS., and PepperbergD.R. (1995). Abnormal activation and inactivation mechanisms of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest. Ophthalmol. Vis. Sci., 36, 1603–1614.
9.
BoyeS.E., BoyeS.L., PangJ., et al. (2010). Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PloS One, 5, e11306.
10.
BoyeS.L., ConlonT., ErgerK., et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest. Ophthalmol. Vis. Sci., 52, 7098–7108.
11.
BoyeS.E., AlexanderJ.J., BoyeS.L., et al. (2012). The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum. Gene Ther., 23, 1101–1115.
12.
Carter-DawsonL.D., and LavailM.M. (1979). Rods and cones in the mouse retina. I. Structural analysis using light and electron microscopy. J. Comp. Neurol., 188, 245–262.
13.
CideciyanA.V., AlemanT.S., BoyeS.L., et al. (2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA, 105, 15112–15117.
14.
CideciyanA.V., HauswirthW.W., AlemanT.S., et al. (2009a). Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20, 999–1004
15.
CideciyanA.V., HauswirthW.W., AlemanT.S., et al. (2009b). Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med., 361, 725–727
16.
CideciyanA.V., JacobsonS.G., BeltranW.A., et al. (2013). Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl. Acad. Sci. USA, 110, E517–E525.
17.
ClarkeG., HeonE., and McinnesR.R. (2000). Recent advances in the molecular basis of inherited photoreceptor degeneration. Clin. Genet., 57, 313–329.
18.
CorboJ.C., MyersC.A., LawrenceK.A., et al. (2007). A typology of photoreceptor gene expression patterns in the mouse. Proc. Natl. Acad. Sci. USA, 104, 12069–12074.
19.
Den HollanderA.I., RoepmanR., KoenekoopR.K., and CremersF.P. (2008). Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin. Eye Res., 27, 391–419.
20.
Den HollanderA.I., BlackA., BennettJ., and CremersF.P. (2010). Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J. Clin. Invest., 120, 3042–3053.
21.
GarbersD.L., and LoweD.G. (1994). Guanylyl cyclase receptors. J. Biol. Chem., 269, 30741–30744.
22.
HauswirthW.W., AlemanT.S., KaushalS., et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther., 19, 979–990.
23.
HendricksonA., and HicksD. (2002). Distribution and density of medium- and short-wavelength selective cones in the domestic pig retina. Exp. Eye Res., 74, 435–444.
24.
JacobsonS.G., CideciyanA.V., PeshenkoI.V., et al. (2013). Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum. Mol. Genet., 22, 168–183.
25.
JeonC.J., StrettoiE., and MaslandR.H. (1998). The major cell populations of the mouse retina. J. Neurosci., 18, 8936–8946.
26.
KaraliM., PelusoI., MarigoV., and BanfiS. (2007). Identification and characterization of microRNAs expressed in the mouse eye. Invest. Ophthalmol. Vis. Sci., 48, 509–515.
27.
KaraliM., ManfrediA., PuppoA., et al. (2011). MicroRNA-restricted transgene expression in the retina. PloS One, 6, e22166.
28.
KhaniS.C., PawlykB.S., BulgakovO.V., et al. (2007). AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest. Ophthalmol. Vis. Sci., 48, 3954–3961.
29.
LaiC.M., YuM.J., BrankovM., et al. (2004). Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65−/− knockout mouse eye results in limited rescue. Genet. Vaccines Ther., 2, 3.
30.
LebherzC., MaguireA., TangW., et al. (2008). Novel AAV serotypes for improved ocular gene transfer. J. Gene Med., 10, 375–382.
31.
LiA., ZhuX., and CraftC.M. (2002). Retinoic acid upregulates cone arrestin expression in retinoblastoma cells through a Cis element in the distal promoter region. Invest. Ophthalmol. Vis. Sci., 43, 1375–1383.
32.
MaguireA.M., SimonelliF., PierceE.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
33.
MaguireA.M., HighK.A., AuricchioA., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 374, 1597–1605.
34.
MancusoK., HauswirthW.W., LiQ., et al. (2009). Gene therapy for red-green colour blindness in adult primates. Nature, 461, 784–787.
35.
MieziewskaK. (1996). The interphotoreceptor matrix, a space in sight. Microsc. Res. Tech., 35, 463–471.
36.
MihelecM., PearsonR.A., RobbieS.J., et al. (2011). Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum. Gene Ther., 22, 1179–1190.
37.
MussolinoC., Della CorteM., RossiS., et al. (2011). AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther., 18, 637–645.
38.
OmriS., OmriB., SavoldelliM., et al. (2010). The outer limiting membrane (OLM) revisited: clinical implications. Clin. Ophthalmol., 4, 183–195.
39.
PasadhikaS., FishmanG.A., StoneE.M., et al. (2010). Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci., 51, 2608–2614.
40.
PawlykB.S., BulgakovO.V., LiuX., et al. (2010). Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis. Hum. Gene Ther., 21, 993–1004.
41.
PerraultI., RozetJ.M., GerberS., et al. (2000). Spectrum of retGC1 mutations in Leber's congenital amaurosis. Eur. J. Hum. Genet., 8, 578–582.
42.
PetitL., LheriteauE., WeberM., et al. (2012). Restoration of vision in the pde6beta-deficient dog, a large animal model of rod-cone dystrophy. Mol. Ther., 20, 2019–2030.
43.
SeeligerM.W., BrombasA., WeilerR., et al. (2011). Modulation of rod photoreceptor output by HCN1 channels is essential for regular mesopic cone vision. Nat. Commun., 2, 532.
44.
SimonelliF., MaguireA.M., TestaF., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 18, 643–650.
45.
StiegerK., and LorenzB. (2010). Gene therapy for vision loss—recent developments. Discov. Med., 10, 425–433.
46.
SunX., PawlykB., XuX., et al. (2010). Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther., 17, 117–131.
47.
SundaramV., MooreA.T., AliR.R., and BainbridgeJ.W. (2012). Retinal dystrophies and gene therapy. Eur. J. Pediatr., 171, 757–765.
48.
SuraceE.M., and AuricchioA. (2008). Versatility of AAV vectors for retinal gene transfer. Vis. Res., 48, 353–359.
49.
TestaF., MaguireA.M., RossiS., et al. (2013). Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology, 120, 1283–1291.
50.
VandenbergheL.H., and AuricchioA. (2012). Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther., 19, 162–168.
51.
VandenbergheL.H., BellP., MaguireA.M., et al. (2011). Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci. Transl. Med., 3, 88ra54.
52.
VandenbergheL.H., BellP., MaguireA.M., et al. (2013). AAV9 targets cone photoreceptors in the nonhuman primate retina. PloS One, 8, e53463.
53.
WeissE.R., DucceschiM.H., HornerT.J., et al. (2001). Species-specific differences in expression of G-protein-coupled receptor kinase (GRK) 7 and GRK1 in mammalian cone photoreceptor cells: implications for cone cell phototransduction. J. Neurosci., 21, 9175–9184.
54.
YangR.B., RobinsonS.W., XiongW.H., et al. (1999). Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J. Neurosci., 19, 5889–5897.
55.
YoungJ.E., VogtT., GrossK.W., and KhaniS.C. (2003). A short, highly active photoreceptor-specific enhancer/promoter region upstream of the human rhodopsin kinase gene. Invest. Ophthalmol. Vis. Sci., 44, 4076–4085.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
